Dynamics of circulating tumor cells in early breast cancer under neoadjuvant therapy

José Serrano,María; Sánchez Rovira,Pedro; Martínez-Zubiaurre,I.; Delgado Rodriguez,Miguel; Fernández,Mónica; Lorente,Jose  A.

doi:10.3892/etm.2012.540

Dynamics of circulating tumor cells in early breast cancer under neoadjuvant therapy

Authors:
- María José Serrano
- Pedro Sánchez Rovira
- I. Martínez-Zubiaurre
- Miguel Delgado Rodriguez
- Mónica Fernández
- Jose A. Lorente
View Affiliations

Affiliations: Centro Pfizer, Universidad de Granada, Junta de Andalucía de Genómica e Investigación Oncológica (GENYO), Granada, Spain, Medical Oncology Department, University Hospital, Jaén, Spain, Institute of Clinical Medicine, University of Tromso, Tromso, Norway, Department of Health Sciences, Faculty of Experimental Sciences, University of Jaén, Jaén, Spain
Published online on: April 5, 2012 https://doi.org/10.3892/etm.2012.540
Pages: 43-48

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

At present, the majority of patients with breast cancer are diagnosed at early stages of disease development. However, a considerable number of such cases develop secondary malignancies after a relatively short period of time. The presence of circulating tumor cells (CTCs) has been proposed as a strong biomarker to predict disease recurrence in metastatic breast cancer. However, the prognostic significance is not clear in early breast cancer. We present results on CTC determination in peripheral blood in non-metastatic breast cancer patients in the context of neoadjuvant treatment. Twenty-six breast cancer patients, scheduled for neoadjuvant therapy, were enrolled in a prospective study, of which 24 were able to complete therapy. CTC assessment was performed by sorting out cytokeratin-positive cells from 10 ml of peripheral blood using immunomagnetic separation, followed by immunocytochemical characterization of cells. Seventeen blood samples out of 24 patients were CTC-positive when collected prior to neoadjuvant chemotherapy. No significant correlations were found between the presence of CTCs and lymph node status (p=0.1), histological type (p=0.802), stage (p=0.43) or overall survival (OS) (p=0.599). Thirteen CTC-positive samples were observed in blood samples collected after treatment. Univariate analyses revealed that the presence of CTCs was related to OS when the detection was positive both before and after treatment (p=0.023). CTCs can be a strong prognostic marker in early breast cancer. The persistence of CTCs before and after treatment can identify a subpopulation of patients with an increased risk of recurrence.

View Figures

View References

1	Klein CA: The metastasis cascade. Science. 321:1841–1844. 2008. View Article : Google Scholar
2	Mego M, Mani SA and Cristofanilli M: Molecular mechanisms of metastasis in breast cancer – clinical applications. Nat Rev Clin Oncol. 7:693–701. 2010.
3	Graves H and Czerniecki BJ: Circulating tumor cells in breast cancer patients: an evolving role in patient prognosis and disease progression. Pathol Res Int. 2011:6210902011. View Article : Google Scholar : PubMed/NCBI
4	Pantel K and Brakenhoff RH: Dissecting the metastatic cascade. Nat Rev Cancer. 4:448–456. 2004. View Article : Google Scholar : PubMed/NCBI
5	Serrano MJ, Sánchez-Rovira P, Delgado-Rodriguez M and Gaforio JJ: Detection of circulating tumor cells in the context of treatment: prognostic value in breast cancer. Cancer Biol Ther. 8:671–675. 2009. View Article : Google Scholar : PubMed/NCBI
6	Botteri E, Sandri MT, Bagnardi V, Munzone E, Zorzino L, Rotmensz N, Casadio C, Cassatella MC, Esposito A, Curigliano G, et al: Modeling the relationship between circulating tumour cell number and prognosis of metastatic breast cancer. Breast Cancer Res Treat. 122:211–217. 2010. View Article : Google Scholar : PubMed/NCBI
7	Lin H, Balic M, Zheng S, Datar R and Cote R: Disseminated and circulating tumor cells: role in effective cancer management. Crit Rev Oncol Hematol. 77:1–11. 2011. View Article : Google Scholar : PubMed/NCBI
8	García-Sáenz JA, Martín M, Maestro ML, Vidaurreta M, Veganzones S, Rafael S, Casado A, Bobokova J, Sastre J, de la Orden V, et al: Circulating tumour cells in locally advanced breast cancer. Clin Transl Oncol. 11:544–547. 2009.
9	Pierga JY, Bidard FC, Mathiot C, Brain E, Delaloge S, Giachetti S, de Cremoux P, Salmon R, Vincent-Salomon A and Marty M: Circulating tumor cell detection predicts early metastatic relapse after neoadjuvant chemotherapy in large operable and locally advanced breast cancer in a phase II randomized trial. Clin Cancer Res. 14:7004–7010. 2008. View Article : Google Scholar
10	Nakagawa T, Martinez SR, Goto Y, Koyanagi K, Kitago M, Shingai T, Elashoff DA, Ye X, Singer FR, Giuliano AE and Hoon DSB: Detection of circulating tumor cells in early-stage breast cancer metastasis to axillary lymph nodes. Clin Cancer Res. 13:4105–4110. 2007. View Article : Google Scholar : PubMed/NCBI
11	Wong NS, Kahn HJ, Zhang L, Oldfield S, Yang LY, Marks A and Trudeau ME: Prognostic significance of circulating tumour cells enumerated after filtration enrichment in early and metastatic breast cancer patients. Breast Cancer Res Treat. 99:63–69. 2006. View Article : Google Scholar : PubMed/NCBI
12	Langer R, Ott K, Feith M, Lordick F, Siewert JR and Becker K: Prognostic significance of histopathological tumor regression after neoadjuvant chemotherapy in esophageal adenocarcinomas. Mod Pathol. 22:1555–1563. 2009. View Article : Google Scholar
13	Makhoul I and Kiwan E: Neoadjuvant systemic treatment of breast cancer. J Surg Oncol. 103:348–357. 2011. View Article : Google Scholar : PubMed/NCBI
14	Pierga JY, Hajage D, Bachelot T, Delaloge S, Brain E, Campone M, Dieras V, Rolland E, Mignot L, Mathiot C and Bidard FC: High independent prognostic and predictive value of circulating tumor cells compared with serum tumor markers in a large prospective trial in first-line chemotherapy for metastatic breast cancer patients. Ann Oncol. 2011. View Article : Google Scholar : 2011.
15	Riethdorf S and Pantel K: Disseminated tumor cells in bone marrow and circulating tumor cells in blood of breast cancer patients: current state of detection and characterization. Pathobiology. 75:140–148. 2008. View Article : Google Scholar : PubMed/NCBI
16	Gaforio JJ, Serrano MJ, Sanchez-Rovira P, Sirvent A, Delgado-Rodriguez M, Campos M, de la Torre N, Algarra I, Duenas R and Lozano A: Detection of breast cancer cells in the peripheral blood is positively correlated with estrogen-receptor status and predicts for poor prognosis. Int J Cancer. 107:984–990. 2003. View Article : Google Scholar
17	Bidard FC, Mathiot C, Delaloge S, Brain E, Giachetti S, de Cremoux P, Marty M and Pierga JY: Single circulating tumor cell detection and overall survival in nonmetastatic breast cancer. Ann Oncol. 21:729–733. 2010. View Article : Google Scholar : PubMed/NCBI
18	Riethdorf S, Müller V, Zhang L, Rau T, Komor M, Roller M, Huober J, Fehm T, Schrader I, Hilfrich J, et al: Detection and HER2 expression of circulating tumor cells: prospective monitoring in breast cancer patients treated in the neoadjuvant geparquattro trial. Clin Cancer Res. 16:2634–2645. 2010. View Article : Google Scholar
19	Serrano MJ, Lorente JA, Delgado Rodríguez M, Fernández A, Fernández M, de la Torre C, Fernández Izquierdo J and Sánchez Rovira P: Circulating tumour cells in peripheral blood: potential impact on breast cancer outcome. Clin Trans Oncol. 13:204–208. 2011. View Article : Google Scholar : PubMed/NCBI
20	Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Matera J, Miller MC, Reuben JM, Doyle GV, Allard WJ, Terstappen LW and Hayes DF: Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med. 351:781–791. 2004. View Article : Google Scholar : PubMed/NCBI
21	Pachmann K, Camara O, Kavallaris A, Krauspe S, Malarski N, Gajda M, Kroll T, Jörke C, Hammer U, Altendorf-Hofmann A, et al: Monitoring the response of circulating epithelial tumor cells to adjuvant chemotherapy in breast cancer allows detection of patients at risk of early relapse. J Clin Oncol. 26:1208–1215. 2008. View Article : Google Scholar
22	Pachmann K, Camara O, Kohlhase A, et al: Assessing the efficacy of targeted therapy using circulating epithelial tumor cells (CETC): the example of SERM therapy monitoring as a unique tool to individualize therapy. J Cancer Res Clin Oncol. 137:821–828. 2011. View Article : Google Scholar : PubMed/NCBI
23	Meng S, Tripathy D, Frenkel EP, Shete S, Naftalis EZ, Huth JF, Beitsch PD, Leitch M, Hoover S, Euhus D, et al: Circulating tumor cells in patients with breast cancer dormancy. Clin Cancer Res. 10:8152–8162. 2004. View Article : Google Scholar : PubMed/NCBI
24	Aguirre-Ghiso JA: Models, mechanisms and clinical evidence for cancer dormancy. Nat Rev Cancer. 7:834–846. 2007. View Article : Google Scholar : PubMed/NCBI
25	Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY, Brooks M, Reinhard F, Zhang CC, Shipitsin M, et al: The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell. 133:704–715. 2008. View Article : Google Scholar : PubMed/NCBI